AstraZeneca has entered a strategic collaboration with the Lupus Research Alliance and Lupus Therapeutics to accelerate clinical trial recruitment and patient-centered research. The partnership covers several key programs, including the BLOSSOM pediatric trial for anifrolumab-fnia, a CD19/BCMA CAR-T therapy, and the TITAN and ASSURO T-cell engager trials.
AstraZeneca announced a strategic collaboration with the Lupus Research Alliance and Lupus Therapeutics to support recruitment and trial conduct across its lupus programs, including anifrolumab-fnia (BLOSSOM pediatric trial), a CD19/BCMA CAR-T therapy, and the TITAN and ASSURO T-cell engager trials. No financial terms, order value or guidance change is disclosed, so the release is routine pipeline support rather than a price-moving fact.
- • Collaboration announced Nov. 19, 2026 covering several early clinical lupus programs
- • Support for the BLOSSOM pediatric trial of anifrolumab-fnia
- • No deal value, revenue or timeline figures are given
- • The partnership supports existing programs rather than adding new approvals or sales